Revenues up 13.1% year-over-year; Continued momentum driven by organic growth, strategic partnerships, and acquisitions
Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal phase III IMforte study
Saroglitazar was generally well tolerated, with overall adverse events generally balanced between Saroglitazar-treated and placebo-treated patients
Approval based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death for the Imfinzi regimen vs. neoadjuvant chemotherapy alone
The inspection concluded successfully, with the facility found to be in compliance with the required regulations
This global affiliation marks a critical step in the company’s mission to create long-term value through ethical practices, scientific innovation, and inclusive healthcare delivery
This addition strengthens Dr. Agarwals Eye Hospital's vast network of 28 hospitals across Karnataka and 220+ facilities worldwide
Dr. Prabhavathi brings over 14 years of unparalleled experience in pediatrics and a specialized focus on neurodevelopmental disorders
AA Signature provides an innovative approach to treatment planning that focuses on patient outcomes
QUANTI clinical development program evaluated the efficacy and safety of the investigational MRI contrast agent gadoquatrane for a broad range of potential indications and in pediatric and adult patients
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
